Ascendis Pharma A/S Announces TransCon Growth Hormone Oral and Poster Presentations at ENDO 2016
Prof.
Prof. Chatelain commented, "TransCon Growth Hormone's unique design makes it the only long-acting growth hormone in development that provides a sustained-release of native recombinant growth hormone to the patient. The positive Phase 2 trial results presented at
Additionally, Ascendis made two poster presentations during the conference, which are currently available on its corporate website, www.ascendispharma.com/product-pipeline/publications:
- "Pediatric Phase 2 Data Demonstrate that TransCon hGH has an Anti-hGH Immunogenic Profile that is Comparable to Daily hGH", (Gilfoyle, et al.)
- "Pharmacokinetic Model Guided Design of TransCon Growth Hormone, to Ensure Unmodified Growth Hormone Levels Comparable to Daily Growth Hormone", (Sprogøe, et al.)
About
Additionally,
The TransCon technology combines the benefits of prodrug and sustained-release technologies, and is the key driver of
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding our future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to our product pipeline, including our plans to initiate our global Phase 3 heiGHt trial in GHD children in mid-2016. We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make, including the following: unforeseen safety or efficacy results in our lead development program TransCon Growth Hormone or other development programs; unforeseen expenses related to the development of TransCon Growth Hormone or other development programs, general and administrative expenses, other research and development expenses and our business generally; delays in the development of TransCon Growth Hormone related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug for planned clinical studies; and our ability to obtain additional funding, if needed, to support our business activities. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to our business in general, see our current and future reports filed with, or submitted to, the
Investor contact:
Chief Business Officer
(650) 352-8389
ir@ascendispharma.com
Logo - http://photos.prnewswire.com/prnh/20150824/260617LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ascendis-pharma-as-announces-transcon-growth-hormone-oral-and-poster-presentations-at-endo-2016-300245233.html
SOURCE